English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In this study, the  166 Ho-triethylene tetramine hexa (methylene phosphonic acid) ( 166 Ho-TTHMP) complex was prepared as a bone palliation agent. The complex was successfully prepared using an in-house synthesized TTHMP ligand and [ 166 Ho]HoCl 3 . Ho-166 chloride was obtained by thermal neutron irradiation (1×10 13  n cm −2  s −1 ) of natural Ho(NO 3 ) 3  samples, followed by radiolabeling and stability studies. Biodistribution studies were also performed in wild type rats. The complex was prepared with the specific activity of 3–5 GBq/mg and a high radiochemical purity &gt; 99%, (checked by ITLC). The  166 Ho-TTHMP complex was stable in the final preparation and in the presence of human serum (&gt; 90%) up to 72 h. The biodistribution of  166 Ho-TTHMP in wild-type rats demonstrated significant bone uptake compared to  166 HoCl 3  up to 48 h. SPECT imaging of the radiolabeled compound was demonstrated to be in complete accordance with the biodistribution data. The major uptake was observed for long bones including thigh bones as well as skull and also knee and vertebrae. Primary properties of  166 Ho-TTHMP demonstrate that this new therapeutic agent can be a good choice for metastatic bone pains.

The synthesis, radiolabeling and first biological evaluation of a new 166 Ho-complex for radiotherapy of bone metastases